Cargando…

Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment

Between 5% and 10% of women have distant metastases when they receive a breast cancer (BC) diagnosis. Metastatic BC is associated with poor prognosis but advances in systemic treatments have improved survival rates in recent decades. Debates about local primary tumour management in metastatic stages...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berwart, Julia, Peccatori, Fedro A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592705/ https://www.ncbi.nlm.nih.gov/pubmed/31281427 http://dx.doi.org/10.3332/ecancer.2019.930

Ejemplares similares

Locoregional treatment of breast cancer during pregnancy
por: Toesca, Antonio, et al.
Publicado: (2014)

Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery
por: Buonomo, Barbara, et al.
Publicado: (2019)

Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences
por: Peccatori, Fedro Alessandro, et al.
Publicado: (2018)

Chronic lymphocytic leukaemia during pregnancy: management and thoughts
por: Winckler, Patricia, et al.
Publicado: (2015)

Guidelines for Cancer Treatment during Pregnancy: Ethics-Related Content Evolution and Implications for Clinicians
por: Linkeviciute, Alma, et al.
Publicado: (2022)

Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
por: Megaro, Giacomina, et al.
Publicado: (2020)

Psychological issues and construction of the mother-child relationship in women with cancer during pregnancy: a perspective on current and future directions
por: Ferrari, Federica, et al.
Publicado: (2018)

Quality of life during chemotherapy, hormonotherapy or antiHER2 therapy of patients with advanced, metastatic breast cancer in clinical practice
por: Adamowicz, Krzysztof, et al.
Publicado: (2020)

Cancer During Pregnancy: The Role of Vascular Toxicity in Chemotherapy-Induced Placental Toxicity
por: Bar-Joseph, Hadas, et al.
Publicado: (2020)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer
por: Candás, Gabriela, et al.
Publicado: (2021)

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
por: Wynn, Carrie S., et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
por: Azim, Hatem A, et al.
Publicado: (2015)

Seeing beyond COVID-19: understanding the impact of the pandemic on oncology, and the importance of preparedness
por: Carrieri, Daniele, et al.
Publicado: (2020)

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
por: Moilanen, Tiina, et al.
Publicado: (2017)

“Lights and Shadows”: An Interpretative Phenomenological Analysis of the Lived Experience of Being Diagnosed With Breast Cancer During Pregnancy
por: Facchin, Federica, et al.
Publicado: (2021)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Pregnancy in a Young Patient with Metastatic HER2-Positive Breast Cancer—Between Fear of Recurrence and Desire to Procreate
por: Oprean, Cristina Marinela, et al.
Publicado: (2023)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Uterine irradiation as a determinant of infertility and pregnancy losses in young cancer survivors
por: Buonomo, Barbara, et al.
Publicado: (2020)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Frequency of Pregnancy-Associated Cancer: A Systematic Review of Population-Based Studies
por: Dalmartello, Michela, et al.
Publicado: (2020)

Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer
por: Chen, Hao-ran, et al.
Publicado: (2017)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Surgical Treatment Following Failed Medical Treatment of an Interstitial Pregnancy
por: Restaino, Stefano, et al.
Publicado: (2022)

COVID-19: a plea to protect the older population
por: Carrieri, Daniele, et al.
Publicado: (2020)

The Oncohumanities training programme: Fostering a deeper engagement and integration of oncology and humanities to tackle the pressing and complex challenges of cancer care
por: Carrieri, Daniele, et al.
Publicado: (2023)

Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma
por: Makary, Mina S, et al.
Publicado: (2018)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
por: Gómez-Martin, Carlos, et al.
Publicado: (2012)

Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
por: Liu, Qiuyue, et al.
Publicado: (2022)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_42ld7d1tha6asie1150obltj7h